Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing

Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing Mythic’s FateControl™ technology holds the potential to dramatically improve the therapeutic index of ADCs, independent of the linker and payload Series B proceeds to finance lead program through first-in-human clinical studies in lung cancer and fund pipeline development Waltham, Mass., December 15, 2021 (Business Wire) – Mythic Therapeutics today announced its launch to develop smarter and safer antibody-drug conjugates (ADCs) with an oversubscribed Series B financing round of $103 million. The proceeds from Mythic’s Series B will finance the lead program through first-in-human clinical studies in lung cancer and fund pipeline development. “To date, approaches to improve the performance of ADCs have focused primarily on innovation in one of three dimensions: linker and payload chemistries, conjugation technology, and new target biology,” said Brian Fiske, PhD, co-founder and Chief Scientific Officer of Mythic Therapeutics. However, studies have demonstrated that the vast majority of payload is ultimately released non-specifically throughout the body, causing systemic toxicity and reducing efficacy. “The progress this team has made in a short time reinforces our deep conviction in Mythic’s ability to develop a pipeline of safer and more effective ADCs, beginning with their lead program.